Somewhat Favorable News Coverage Somewhat Unlikely to Affect Aradigm Corporation (ARDM) Stock Price
Media coverage about Aradigm Corporation (NASDAQ:ARDM) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aradigm Corporation earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.5773886977601 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the headlines that may have effected Accern’s analysis:
- Gaps Down – IZEA, TTS, ARDM, ITCI, CLXT, BCOM, CARV (fxpips.com)
- Contrasting Aradigm Corporation (ARDM) & Its Competitors (americanbankingnews.com)
- Aradigm : Announces FDA Acceptance of NDA for Linhaliq with Priority Review Status (4-traders.com)
- U.S. Futures Cautiously Lower Ahead of Speakers, Data (nasdaq.com)
- Pro-Trader Daily: Corporate News Blog – Aradigm Announces FDA Acceptance of Priority Review Status for its NDA for Linhaliq (finanznachrichten.de)
ARDM has been the subject of several research reports. Zacks Investment Research cut Aradigm Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, September 27th. Ladenburg Thalmann Financial Services reissued a “buy” rating and issued a $10.00 price target (up previously from $7.50) on shares of Aradigm Corporation in a report on Monday, September 25th.
Shares of Aradigm Corporation (NASDAQ ARDM) opened at 4.20 on Monday. The stock’s 50 day moving average is $1.32 and its 200 day moving average is $1.39. The firm’s market capitalization is $60.61 million. Aradigm Corporation has a 12 month low of $0.78 and a 12 month high of $6.88.
Aradigm Corporation (NASDAQ:ARDM) last released its quarterly earnings results on Thursday, August 10th. The company reported $0.07 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.37. The business had revenue of $7.68 million during the quarter. Aradigm Corporation had a negative return on equity of 665.03% and a negative net margin of 196.65%. Equities research analysts forecast that Aradigm Corporation will post ($0.74) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Aradigm Corporation (ARDM) Stock Price” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/02/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-aradigm-corporation-ardm-stock-price.html.
Aradigm Corporation Company Profile
Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.
Receive News & Stock Ratings for Aradigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm Corporation and related stocks with our FREE daily email newsletter.